Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Ann N Y Acad Sci
2008 Jan 01;1132:29-41. doi: 10.1196/annals.1405.007.
Show Gene links
Show Anatomy links
Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.
Lindstrom J
,
Luo J
,
Kuryatov A
.
???displayArticle.abstract???
The main immunogenic region (MIR), against which half or more of the autoantibodies to acetylcholine receptors (AChRs) in myasthenia gravis (MG) or experimental autoimmune MG (EAMG) are directed, is located at the extracellular end of alpha1 subunits. Rat monoclonal antibodies (mAbs) to the MIR efficiently compete with MG patient autoantibodies for binding to human muscle AChRs. Antibodies bound to the MIR do not interfere with cholinergic ligand binding or AChR function, but target complement and trigger antigenic modulation. Rat mAbs to the MIR also bind to human ganglionic AChR alpha3 subunits, but MG patient antibodies do not. By making chimeras of alpha1 subunits with alpha7 subunits or ACh binding protein, the structure of the MIR and its functional effects are being investigated. Many mAbs to the MIR bind only to the native conformation of alpha1 subunits because they bind to sequences that are adjacent only in the native structure. The MIR epitopes recognized by these mAbs are not recognized by most patient antibodies whose epitopes must be nearby. The presence of the MIR epitopes in alpha1/alpha7 chimeras greatly promotes AChR expression and sensitivity to activation. EAMG can be suppressed by treatment with denatured, bacterially expressed mixtures of extracellular and cytoplasmic domains of human alpha1, beta1, gamma, delta, and epsilon subunits. A mixture of only the cytoplasmic domains not only avoids the potential liability of provoking formation antibodies to pathologically significant epitopes on the extracellular surface, but also potently suppresses the development of EAMG.
Amit,
Three-dimensional structure of an antigen-antibody complex at 6 A resolution.
, Pubmed
Amit,
Three-dimensional structure of an antigen-antibody complex at 6 A resolution.
,
Pubmed
Barchan,
Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
1998,
Pubmed
Bartfeld,
Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.
1978,
Pubmed
Beroukhim,
Three-dimensional location of the main immunogenic region of the acetylcholine receptor.
1995,
Pubmed
Bocquet,
A prokaryotic proton-gated ion channel from the nicotinic acetylcholine receptor family.
2007,
Pubmed
,
Xenbase
Bouzat,
Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel.
2004,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Celie,
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.
2004,
Pubmed
Conti-Tronconi,
Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor.
1981,
Pubmed
Das,
Epitope mapping of antibodies to acetylcholine receptor alpha subunits using peptides synthesized on polypropylene pegs.
1991,
Pubmed
Drachman,
Oral tolerance in myasthenia gravis.
1996,
Pubmed
Elgoyhen,
alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
2001,
Pubmed
,
Xenbase
Engel,
Sleuthing molecular targets for neurological diseases at the neuromuscular junction.
2003,
Pubmed
Fenster,
Regulation of alpha4beta2 nicotinic receptor desensitization by calcium and protein kinase C.
1999,
Pubmed
,
Xenbase
Froehner,
Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica.
1981,
Pubmed
Gotti,
Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
2006,
Pubmed
Grando,
Cholinergic control of epidermal cohesion.
2006,
Pubmed
Grando,
Autoimmunity to keratinocyte acetylcholine receptors in pemphigus.
2000,
Pubmed
Hales,
Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha4beta2 nicotinic acetylcholine receptors.
2006,
Pubmed
Halevi,
The C. elegans ric-3 gene is required for maturation of nicotinic acetylcholine receptors.
2002,
Pubmed
,
Xenbase
Hansen,
Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations.
2005,
Pubmed
Henchman,
Asymmetric structural motions of the homomeric alpha7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation.
2003,
Pubmed
Im,
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
1999,
Pubmed
Im,
Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.
2000,
Pubmed
Im,
Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.
2000,
Pubmed
Kalamida,
Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity.
2007,
Pubmed
Karachunski,
Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis.
1999,
Pubmed
Karlin,
Emerging structure of the nicotinic acetylcholine receptors.
2002,
Pubmed
Keyser,
Three subtypes of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors are expressed in chick retina.
1993,
Pubmed
Klaassen,
Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy.
2006,
Pubmed
Konstantakaki,
Molecular modeling of the complex between Torpedo acetylcholine receptor and anti-MIR Fab198.
2007,
Pubmed
Kontou,
The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor.
2000,
Pubmed
Krolick,
Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
1996,
Pubmed
Kuryatov,
Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors.
1997,
Pubmed
,
Xenbase
Kuryatov,
Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors.
2005,
Pubmed
Lansdell,
RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells.
2005,
Pubmed
,
Xenbase
Liblau,
Systemic antigen in the treatment of T-cell-mediated autoimmune diseases.
1997,
Pubmed
Lindstrom,
Molecular and antigenic structure of nicotinic acetylcholine receptors.
1998,
Pubmed
Lindstrom,
Acetylcholine receptors and myasthenia.
2000,
Pubmed
Lindstrom,
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.
1976,
Pubmed
Lindstrom,
Immunization of rats with polypeptide chains from torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle.
1978,
Pubmed
Loutrari,
Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
1992,
Pubmed
Ma,
Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.
1995,
Pubmed
Maimone,
Interaction of the 43 kd postsynaptic protein with all subunits of the muscle nicotinic acetylcholine receptor.
1993,
Pubmed
Maiti,
Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.
2004,
Pubmed
McLane,
Epitope mapping of polyclonal and monoclonal antibodies against two alpha-bungarotoxin-binding alpha subunits from neuronal nicotinic receptors.
1992,
Pubmed
,
Xenbase
Merlie,
The regulation of acetylcholine receptor expression in mammalian muscle.
1983,
Pubmed
Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Poulas,
Crystal structure of Fab198, an efficient protector of the acetylcholine receptor against myasthenogenic antibodies.
2001,
Pubmed
Protti,
Myasthenia gravis: recognition of a human autoantigen at the molecular level.
1993,
Pubmed
Saedi,
Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis.
1990,
Pubmed
,
Xenbase
Shelton,
Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor.
1988,
Pubmed
Shi,
Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
1999,
Pubmed
Sine,
Recent advances in Cys-loop receptor structure and function.
2006,
Pubmed
Tapia,
Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors.
2007,
Pubmed
,
Xenbase
Tapper,
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization.
2004,
Pubmed
Tracey,
Physiology and immunology of the cholinergic antiinflammatory pathway.
2007,
Pubmed
Tumkosit,
Beta3 subunits promote expression and nicotine-induced up-regulation of human nicotinic alpha6* nicotinic acetylcholine receptors expressed in transfected cell lines.
2006,
Pubmed
,
Xenbase
Tzartos,
Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor.
1998,
Pubmed
Tzartos,
Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits.
1980,
Pubmed
Tzartos,
Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies.
1981,
Pubmed
Tzartos,
Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.
1982,
Pubmed
Tzartos,
Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor.
1983,
Pubmed
Tzartos,
Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor.
1987,
Pubmed
Unwin,
Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
2005,
Pubmed
Vernino,
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes.
1998,
Pubmed
Vernino,
Passive transfer of autoimmune autonomic neuropathy to mice.
2004,
Pubmed
Wang,
B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
1995,
Pubmed
Wang,
Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells.
1998,
Pubmed
,
Xenbase
Weiner,
Oral tolerance for the treatment of autoimmune diseases.
1997,
Pubmed
Williams,
The long internal loop of the alpha 3 subunit targets nAChRs to subdomains within individual synapses on neurons in vivo.
1998,
Pubmed
,
Xenbase
Xiao,
Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases.
1997,
Pubmed
